Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing Protein
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Sclerosteosis is an autosomal recessive sclerosing bone dysplasia characterized by progressive skeletal overgrowth. The majority of affected individuals have been reported in the Afrikaner population of South Africa, where a high incidence of the disorder occurs as a result of a founder effect. Homozygosity mapping in Afrikaner families along with analysis of historical recombinants localized sclerosteosis to an interval of approximately 2 cM between the loci D17S1787 and D17S930 on chromosome 17q12-q21. Here we report two independent mutations in a novel gene, termed "SOST." Affected Afrikaners carry a nonsense mutation near the amino terminus of the encoded protein, whereas an unrelated affected person of Senegalese origin carries a splicing mutation within the single intron of the gene. The SOST gene encodes a protein that shares similarity with a class of cystine knot-containing factors including dan, cerberus, gremlin, prdc, and caronte. The specific and progressive effect on bone formation observed in individuals affected with sclerosteosis, along with the data presented in this study, together suggest that the SOST gene encodes an important new regulator of bone homeostasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutations in genes that have highly enriched expression in osteocytes cause rare bone and mineral disorders.”
From Osteocyte transcriptome mapping identifies a molecular landscape controlling skeletal homeostasis and susceptibility to skeletal disease (2021) · cites this paper as [17]
Citations
Cites
Bone: Formation by Autoinduction
Urist, M. R. (1965) · Science · doi:10.1126/science.150.3698.893 · Cited by 5,546 · cited 1×
“Although this family of morpho-gens was originally identified on the basis of bone-in-ducing activity (Urist 1965), a number of these factors have been shown to be critical for very early stages of embryogenesis and fetal development.”
Prediction of complete gene structures in human genomic DNA
Burge, C., & Karlin, S. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.0951 · Cited by 4,228 · cited 8×
“The novel variant gene (designated “P50gsc3”) predicted by GENSCAN was located between markers D17S951 and D17S1860 (fig.”
InfluentialA comprehensive genetic map of the human genome based on 5,264 microsatellites
Dib, C., Fauré, S., Fizames, C., Samson, D., Drouot, N., Vignal, A., Millasseau, P., Marc, S., Kazan, J., Seboun, E., et al. (1996) · Nature · doi:10.1038/380152a0 · Cited by 2,928 · cited 3×
“D17S1793, D17S1789, D17S951, and D17S1860 within the critical region bounded by D17S1787 and D17S930, an interval of ∼ 2 cM (Dib et al. 1996) on the cytogenetic border between the chromosomal bands 17q12–q21.”
Bone morphogenetic proteins: multifunctional regulators of vertebrate development.
Hogan, B. L. (1996) · Genes & Development · doi:10.1101/gad.10.13.1580 · Cited by 1,962
Therapeutic Approaches to Bone Diseases
Rodan, G. A., & Martin, T. J. (2000) · Science · doi:10.1126/science.289.5484.1508 · Cited by 1,767 · cited 1×
“Currently there is no effective treatment for the restoration of normal bone mass in individuals with pathologically low skeletal density, and there is a large unmet need for therapy that can increase bone deposition in osteoporosis (Rodan and Martin 2000).”
BackgroundEasy calculations of lod scores and genetic risks on small computers.
Lathrop, M. G., & Lalouel, J.-M. (1984) · Europe PMC (PubMed Central) · Cited by 1,526
Faster sequential genetic linkage computations.
Cottingham, R. W., Idury, R. M., & Schäffer, A. A. (1993) · Europe PMC (PubMed Central) · Cited by 1,364
Nonsense-mediated mRNA decayin health and disease
Frischmeyer, P. A. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.10.1893 · Cited by 992 · cited 1×
“The relatively low levels of mutant transcripts observed could be the result of nonsense-mediated mRNA decay, as the inclusion of intronic sequence introduced an in-frame nonsense codon (Frischmeyer and Dietz 1999; Hentze and Kulozik 1999).”
BackgroundHomozygosity Mapping: A Way to Map Human Recessive Traits with the DNA of Inbred Children
Lander, E. S., & Botstein, D. (1987) · Science · doi:10.1126/science.2884728 · Cited by 875
FORMATION AND FUNCTION OF SPEMANN'S ORGANIZER
Harland, R., & Gerhart, J. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.611 · Cited by 839 · cited 1×
“In addition, the requirement for the coordinated expression of negative regulators of BMP activity, such as noggin and chordin, as well as members of the dan family, has been well described (Harland and Gerhart 1997; Sasai and De Robertis 1997; Hsu et al. 1998).”
Background
Research works printed but not linked: 3
- Gardner J (1999) Profound childhood deafness in South Africa: a clinical and molecular genetic approach. Ph.D. thesis, University of Cape Town, Cape Town
- Hausen, 1967, Sklerosteose, Vol. 6, 351
- Peitruschka, 1958, Weitere Mitteilungen über die Marmorknochenkrankheit (Albers-Schonbergsche Krankheit) nebst Bemerkungen zur Differentialdiagnose, Klin Monatbl, 132, 509
Cited by
Items 301–400 of 1,000
Li, C., Ominsky, M. S., Tan, H., Barrero, M., Niu, Q., Asuncion, F., Lee, E. W., Liu, M., Simonet, W. S., Pászty, C., et al. (2011) · Bone · doi:10.1016/j.bone.2011.08.012 · Cited by 75
“Humanswith inherited sclerostin deficiency (sclerosteosis and van Buchem disease) show increased bone mass [1–3].”
BackgroundTreating osteoporosis by targeting parathyroid hormone to bone
Ponnapakkam, T., Katikaneni, R., Sakon, J., Stratford, R. E., & Gensure, R. C. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.015 · Cited by 78
The role of extracellular modulators of canonical Wnt signaling in bone metabolism and diseases
Boudin, E., Fijałkowski, I., Piters, E., & Hul, W. V. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2013.01.004 · Cited by 85
“family of glycoproteins, a family of BMP antagonists [206,214].”
BackgroundWnt modulators in the biotech pipeline
Rey, J., & Ellies, D. L. (2010) · Developmental Dynamics · doi:10.1002/dvdy.22181 · Cited by 71
Acute Effects of Glucocorticoids on Serum Markers of Osteoclasts, Osteoblasts, and Osteocytes
Maresova, K. B., Pavelká, K., & Stepan, J. J. (2012) · Calcified Tissue International · doi:10.1007/s00223-012-9684-4 · Cited by 78
“sclerostin in humans causes the high-bone mass disorders Van Buchem disease [35] and sclerosteosis [36], and Table 2 Pearson product moment correlation between baseline serum concentrations of 25(OH)D, iPTH, and hsCRP and changes from baseline to 96 h in serum biochemical indices in 17 patients treated with glucocorti…”
Marenzana, M., Greenslade, K., Eddleston, A., Okoye, R., Marshall, D., Moore, A., & Robinson, M. K. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30385 · Cited by 73
Huang, Q., & Kung, A. W. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.04.009 · Cited by 86
Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway
Appelman‐Dijkstra, N. M., & Papapoulos, S. E. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0087-0 · Cited by 76
Sclerostin: Therapeutic Horizons Based Upon Its Actions
Costa, A. G., & Bilezikian, J. P. (2012) · Current Osteoporosis Reports · doi:10.1007/s11914-011-0089-5 · Cited by 74
“Although at least five different inactivating mutations of the SOST gene have been identified in sclerosteosis, no mutations have been seen in van Buchem’s disease [15, 16].”
BackgroundInfluentialLi, X., Niu, Q.-T., Warmington, K. S., Asuncion, F. J., Dwyer, D., Grisanti, M., Han, C.-Y., Stolina, M., Eschenberg, M. J., Kostenuik, P. J., et al. (2014) · Endocrinology · doi:10.1210/en.2013-1905 · Cited by 70
Increased glycolysis mediates Wnt7b‐induced bone formation
Chen, H., Ji, X., Lee, W., Shi, Y., Li, B., Abel, E. D., Jiang, D., Huang, W., & Long, F. (2019) · The FASEB Journal · doi:10.1096/fj.201900201rr · Cited by 76
“Subsequently, loss of expression or function of sclerostin, a secreted antagonist ofWnt proteins encoded by the Sclerostin (SOST) gene, was shown to underlie severe osteosclerosis syndromes (5, 6).”
BackgroundMolecular genetics of too much bone
Janssens, K. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.20.2385 · Cited by 72
Complexity of the Wnt/β‑catenin pathway: Searching for an activation model
Tortelote, G. G., dos Reis, R. R., Mendes, F. A., & Abreu, J. G. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.08.008 · Cited by 80
Genetics in Endocrinology: Autosomal dominant osteopetrosis revisited: lessons from recent studies
Bollerslev, J., Henriksen, K., Nielsen, M. F., Brixen, K., & Hul, W. V. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0136 · Cited by 76
Yerges, L. M., Klei, L., Cauley, J. A., Roeder, K., Kammerer, C. M., Moffett, S. P., Ensrud, K. E., Nestlerode, C. S., Marshall, L. M., Hoffman, A. R., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090524 · Cited by 68
Wallace, S. E., Lachman, R. S., Mekikian, P. B., Bui, K. K., & Wilcox, W. R. (2004) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30148 · Cited by 70
The Therapeutic Potential of the Wnt Signaling Pathway in Bone Disorders
Wagner, E. R., Zhu, G., Zhang, B., Luo, Q., Shi, Q., Huang, E., Gao, Y., Gao, J., Kim, S. H., Rastegar, F., et al. (2011) · Current Molecular Pharmacology · doi:10.2174/1874-470211104010014 · Cited by 78
Wnt signaling in bone, kidney, intestine, and adipose tissue and interorgan interaction in aging
Chen, D., Xie, R., Shu, B., Landay, A. L., Wei, C., Reiser, J., Spagnoli, A., Torquati, A., Forsyth, C. B., Keshavarzian, A., et al. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13945 · Cited by 69
Ardawi, M. S., Al-Sibiany, A., Bakhsh, T. M., Rouzi, A. A., & Qari, M. H. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1806-8 · Cited by 75
Genetic epidemiology of age-related osteoporosis and its clinical applications
Cheung, C., Xiao, S., & Kung, A. W. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.106 · Cited by 71
First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function
Piters, E., Çulha, C., Moester, M. J. C., Bezooijen, R. V., Adriaensen, D., Mueller, T. D., Weidauer, S. E., Jennes, K., de Freitas, F., Löwik, C., et al. (2010) · Human Mutation · doi:10.1002/humu.21274 · Cited by 73
Signaling Pathways in Human Skeletal Dysplasias
Baldridge, D., Shchelochkov, O. A., Kelley, B., & Lee, B. (2010) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082908-150158 · Cited by 73
Parathyroid Hormone Signaling in Osteocytes
Wein, M. N. (2017) · JBMR Plus · doi:10.1002/jbm4.10021 · Cited by 74
“This rare Mendelian skeletal disease is caused by mutations in SOST, which encodes the protein sclerostin, an osteocyte-specific secreted WNT inhibitor.((33)) Sclerostin is a tonic inhibitor of bone formation;((34)) therefore, a mechanism through which bone anabolic signals may trigger new osteoblast activity is by re…”
BackgroundSølling, A. S. K., Harsløf, T., & Langdahl, B. (2018) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x18775936 · Cited by 68
Oropharyngeal Skeletal Disease Accompanying High Bone Mass and Novel LRP5 Mutation
Rickels, M. R., Zhang, X., Mumm, S. R., & Whyte, M. P. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041223 · Cited by 67
“These entities are caused by loss-of-function mutations of the SOST gene((9,10)) and share a dramatic increase in endosteal cortical thickening, wide jaw, and osteosclerosis of the skull base, vertebrae, and pelvis where serum ALP activity is”
BackgroundFrom Stem Cells to Bone-Forming Cells
Donsante, S., Palmisano, B., Serafini, M., Robey, P. G., Corsi, A., & Riminucci, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083989 · Cited by 76
“Ablation of Gsα in mouse Osx promoter-expressing cells leads to a high level of expression of the WNT inhibitors, Sclerostin and dickkopf1 (DKK1) [128].”
BackgroundInfluentialDental and periodontal phenotype in sclerostin knockout mice
Kuchler, U., Schwarze, U. Y., Dobsak, T., Heimel, P., Bosshardt, D. D., Kneissel, M., & Gruber, R. (2014) · International Journal of Oral Science · doi:10.1038/ijos.2014.12 · Cited by 66
Holdsworth, G., Greenslade, K. J., Jose, J., Stencel, Z., Kirby, H., Moore, A., Ke, H. Z., & Robinson, M. K. (2017) · Bone · doi:10.1016/j.bone.2017.11.003 · Cited by 69
Role of nutritional vitamin D in osteoporosis treatment
Hou, Y., Wu, C., Liao, M.-T., Shyu, J., Hung, C., Yen, T., Lu, C., & Lu, K. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.05.035 · Cited by 70
Ohyama, Y., Nifuji, A., MAEDA, Y. Y., Amagasa, T., & Noda, M. (2004) · Endocrinology · doi:10.1210/en.2003-1492 · Cited by 69
“due to excessive mineral deposition (7).”
Séror, R., Boudaoud, S., Pavy, S., Nocturne, G., Schaeverbeke, T., Saraux, A., Chanson, P., Gottenberg, J., Devauchelle‐Pensec, V., Tobón, G. J., et al. (2016) · Scientific Reports · doi:10.1038/srep18421 · Cited by 67
Cardiovascular Safety and Sclerostin Inhibition
Langdahl, B. L., Hofbauer, L. C., & Forfar, J. C. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab193 · Cited by 67
Osteocytic FGF23 and Its Kidney Function
Agoro, R., Ni, P., Noonan, M. L., & White, K. E. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00592 · Cited by 67
Stürznickel, J., Rolvien, T., Delsmann, A., Butscheidt, S., Barvencik, F., Mundlos, S., Schinke, T., Kornak, U., Amling, M., & Oheim, R. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4197 · Cited by 64
Cavalier, E., Bergmann, P., Bruyère, O., Delanaye, P., Durnez, A., Devogelaer, J.-P., Ferrari, S. L., Gielen, E., Goemaere, S., Kaufman, J.-M., et al. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3561-3 · Cited by 63
“bone mass [12].”
Negative Regulation of Bone Formation by the Transmembrane Wnt Antagonist Kremen-2
Schulze, J., Seitz, S., Saito, H., Schneebauer, M., Marshall, R. P., Baranowsky, A., Busse, B., Schilling, A. F., Friedrich, F. W., Albers, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010309 · Cited by 62
“bone mass conditions caused by excessive bone formation [8,9].”
BackgroundPower, J., Poole, K. E. S., Bezooijen, R. V., Doube, M., Caballero-Alías, A. M., Löwik, C. W. G. M., Papapoulos, S. E., REEVE, J., & Loveridge, N. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.70 · Cited by 67
“Recessive genetic disorders resulting in loss of sclerostin cause the clinical high-bone-mass disorders sclerosteosis((21,22)) and van Buchem disease.”
BackgroundThe bone-sparing effects of estrogen and WNT16 are independent of each other
Movérare‐Skrtic, S., Wu, J., Henning, P., Gustafsson, K. L., Sjögren, K., Windahl, S. H., Koskela, A., Tuukkanen, J., Börjesson, A., Lagerquist, M. K., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520408112 · Cited by 67
Clinical and Biological Determinants of Sclerostin Plasma Concentration in Hemodialysis Patients
Delanaye, P., Krzesinski, J.-M., Warling, X., Moonen, M., Smelten, N. S., Médart, L., Bruyère, O., Reginster, J., Pottel, H., & Cavalier, E. (2014) · Nephron Clinical Practice · doi:10.1159/000366449 · Cited by 65
TGF-β regulates sclerostin expression via the ECR5 enhancer
Loots, G. G., Keller, H., Leupin, O., Murugesh, D. K., Collette, N. M., & Genetos, D. C. (2011) · Bone · doi:10.1016/j.bone.2011.11.016 · Cited by 66
“As activating mutations in LRP4-6 promote high bone mass (HBM) phenotypes [1, 2, 7, 8], complementary phenotypes emerge from deletion of Lrp4/5/6 antagonists [9–15]: deletion of sFRPs increases trabecular bone [15] and bone mineral density [14], and deletion of DKK isoforms or SOST increases markers of bone formation…”
BackgroundSclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges
MacNabb, C., Patton, D., & Hayes, J. S. (2016) · Journal of Osteoporosis · doi:10.1155/2016/6217286 · Cited by 67
“Nevertheless, its expression in chondrocytes, osteoblasts, the bone marrow, heart, pancreas, liver, and some foetal tissue has been reported [15– 17].”
BackgroundLRP4 in neuromuscular junction and bone development and diseases
Shen, C., Xiong, W., & Mei, L. (2015) · Bone · doi:10.1016/j.bone.2015.05.012 · Cited by 65
van Dinther, M., Zhang, J., Weidauer, S. E., Boschert, V., Muth, E.-M., Knappik, A., de Gorter, D. J. J., van Kasteren, P. B., Frisch, C., Mueller, T. D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062295 · Cited by 65
“inactivation of its product Sclerostin [11,12].”
Yavropoulou, M. P., van Lierop, A. H., Hamdy, N. A. T., Rizzoli, R., & Papapoulos, S. E. (2012) · Bone · doi:10.1016/j.bone.2012.04.016 · Cited by 63
“Sclerostin has attracted much attention over the last few years due to its implication in the pathogenesis of two rare skeletal disorders characterized by substantial increase in bone mass, sclerosteosis and van Buchem disease [6-9].”
BackgroundPharmacological and biological therapeutic strategies for osteogenesis imperfecta
Marom, R., Lee, Y., Grafe, I., & Lee, B. (2016) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31532 · Cited by 72
“Pathogenic loss-of-function variants in the SOST gene cause sclerosteosis, a rare disorder characterized by high bone mass [Balemans et al., 2001; Brunkow et al., 2001].”
Wang, T., Yu, X., & He, C. (2018) · Current Drug Targets · doi:10.2174/1389450119666180405094046 · Cited by 64
Sclerostin Deficiency Is Linked to Altered Bone Composition
Hassler, N., Roschger, A., Gamsjaeger, S., Krämer, I., Lueger, S., van Lierop, A. H., Roschger, P., Klaushofer, K., Paschalis, E. P., Kneissel, M., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2259 · Cited by 61
The Bone Morphogenetic Proteins and Their Antagonists
Mulloy, B., & Rider, C. C. (2015) · Vitamins and hormones · doi:10.1016/bs.vh.2015.06.004 · Cited by 67
Role of Sclerostin in Cardiovascular Disease
Golledge, J., & Thanigaimani, S. (2022) · Arteriosclerosis, Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317635 · Cited by 47
Single-Cell RNA Sequencing of Calvarial and Long-Bone Endocortical Cells
Ayturk, U. M., Scollan, J. P., Aytürk, D. G., Suh, E. S., Vesprey, A., Jacobsen, C. M., Pajevic, P. D., & Warman, M. L. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4052 · Cited by 60
“In humans, SOST deficiency causes two high bone mass disorders sclerosteosis and Van Buchem disease,((19,20)) which are recapitulated by Sost-null mice.”
BackgroundMundy, G. R., Oyajobi, B. O., Gutierrez, G. E., Sterling, J. A. R., Padalecki, S. S., Elefteriou, F., & Zhao, M. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50020-3 · Cited by 61
Tian, X., Setterberg, R. B., Li, X., Pászty, C., Ke, H. Z., & Jee, W. S. S. (2010) · Bone · doi:10.1016/j.bone.2010.05.032 · Cited by 61
“Genetics and gene expression analysis have demonstrated that the osteocyte-secreted protein sclerostin, encoded by the SOST gene, is a potent inhibitor of bone formation [6–9].”
BackgroundBone Regulates Glucose Metabolism as an Endocrine Organ through Osteocalcin
Shao, J., Wang, Z., Yang, T., Ying, H., Zhang, Y., & Liu, S. (2015) · International Journal of Endocrinology · doi:10.1155/2015/967673 · Cited by 57
Al-Barghouthi, B. M., Mesner, L. D., Calabrese, G. M., Brooks, D. J., Tommasini, S. M., Bouxsein, M., Horowitz, M. C., Rosen, C. J., Nguyen, K. K., Haddox, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23649-0 · Cited by 62
Simmons, D. G., & Kennedy, T. G. (2002) · Biology of Reproduction · doi:10.1095/biolreprod.102.006858 · Cited by 56
“The conservation of the specific pattern of nine amino acids, eight cystines and a glycine, is consistent with USAG-1 being in a class of secreted proteins that contain the cystine knotlike motif; these include the transforming growth factor-b superfamily, the Norrie disease protein, the mucins, and von Willebrand fac…”
BackgroundManolagas, S. C. (2006) · BoneKEy-Osteovision · doi:10.1138/20060193 · Cited by 55
“Importantly, loss of SOST in humans causes the high bone mass disorders van Buchem’s disease (OMIM 239100) (48) and sclerosteosis (OMIM 269500) (49), and an anti-sclerostin antibody increases bone formation in mice (50).”
BackgroundNeumann, T. E., Hofbauer, L. C., Rauner, M., Lodes, S., Kästner, B., Franke, S., Kiehntopf, M., Lehmann, T., Müller, U. A., Wolf, G., et al. (2013) · Clinical Endocrinology · doi:10.1111/cen.12364 · Cited by 57
Heritable sclerosing bone disorders: Presentation and new molecular mechanisms
de Vernejoul, M. C., & Kornak, U. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05244.x · Cited by 59
Jastrzebski, S., Kalinowski, J., Stolina, M., Mirza, F., Torreggiani, E., Kalajzic, I., Won, H. Y., Lee, S.-K., & Lorenzo, J. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1773 · Cited by 51
“Based on its known actions on bone,((18)) decreases in sclerostin production would be expected to increase bone formation rates because loss or inhibition of sclerostin is associated with increased bone mass in both animal models and in humans.((1,2,13,15)) Previous studies from our group((29)) and others((22,30,31,42…”
BackgroundThe Role of Connexin Channels in the Response of Mechanical Loading and Unloading of Bone
Riquelme, M. A., Cardenas, E. R., Xu, H., & Jiang, J. X. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031146 · Cited by 53
“Loss-of-function mutations in the SOST gene (encoding sclerostin) cause osteosclerosis and van Buchem disease with abnormally high bone mass [39,40], suggesting that bone formation is usually suppressed by sclerostin through the inhibition of Wnt/β-catenin signals.”
BackgroundBasha, G., Ordobadi, M., Scott, W. R., Cottle, A., Liu, Y., Wang, H., & Cullis, P. R. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.68 · Cited by 52
Wang, F., Tarkkonen, K. M., Nieminen-Pihala, V., Nagano, K., Majidi, R. A., Puolakkainen, T., Rummukainen, P., Lehto, J., Roivainen, A., Zhang, F., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3680 · Cited by 54
Identification of Sclerostin as a Putative New Myokine Involved in the Muscle-to-Bone Crosstalk
Magarò, M. S., Bertacchini, J., Florio, F., Zavatti, M., Potì, F., Cavani, F., Amore, E., Santis, I. D., Bevilacqua, A., Bonetti, L. R., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9010071 · Cited by 54
“In our study, for the first time, we clearly identified a new putative myokine, sclerostin, that until recently had been described as a potent inhibitor of bone formation produced mainly by osteocytes [23,24].”
BackgroundLiu, Y., Han, X., Bo, J.-X., & Ma, H. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00375 · Cited by 53
“In addition, to counterbalance the activity of these stimulatory coupling factors, osteoblasts can produce inhibitory coupling factors, including osteoprotegerin, sclerostin, bone morphogenetic protein 6 (BMP6), and Wnt10b (Balemans et al., 2001; Brunkow et al., 2001; Bennett et al., 2005, 2007).”
Yee, C. S., Manilay, J. O., Chang, J. C., Hum, N. R., Murugesh, D. K., Bajwa, J., Mendez, M. E., Economides, A. E., Horan, D. J., Robling, A. G., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3467 · Cited by 50
“3-Cre-driven recombination); (3) early-stage osteocytes (Dmp1-Cre-driven recombination); and (4) hypertrophic chondrocytes and their progenitors (ColX-Cre).”
BackgroundInfluentialGenetic evidence that SOST inhibits WNT signaling in the limb
Collette, N. M., Genetos, D. C., Murugesh, D., Harland, R. M., & Loots, G. G. (2010) · Developmental Biology · doi:10.1016/j.ydbio.2010.03.021 · Cited by 49
“Examination of SOST and its paralog, SOSTDC1 has revealed that these molecules can behave both as BMP-(Kassai et al., 2005; Laurikkala et al., 2003; Winkler et al., 2003) and WNTantagonists (Ellies et al., 2006; Itasaki et al., 2003; van Bezooijen et al., 2004; van Bezooijen et al., 2007; Lin et al., 2009), generating…”
BackgroundInfluentialThe role of stromal cells in inflammatory bone loss
Wehmeyer, C., Pap, T., Buckley, C. D., & Naylor, A. J. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.12979 · Cited by 50
Parathyroid hormone inhibits Notch signaling in osteoblasts and osteocytes
Zanotti, S., & CANALIS, E. M. (2017) · Bone · doi:10.1016/j.bone.2017.06.027 · Cited by 48
Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis
Lewiecki, E. M., Shah, A. D., & Shoback, D. (2015) · International Journal of Women s Health · doi:10.2147/ijwh.s73244 · Cited by 70
SOST and DKK: Antagonists of LRP Family Signaling as Targets for Treating Bone Disease
Mason, J. J., & Williams, B. O. (2010) · Journal of Osteoporosis · doi:10.4061/2010/460120 · Cited by 50
“This gene which encodes a secreted glycoprotein (Sclerostin or Sost) containing a cysteine knot-like domain with homology to the Cerebrus/DAN family of BMP antagonists [63, 64].”
Pflanz, D., Birkhold, A. I., Albiol, L., Thiele, T., Julien, C., Seliger, A., Thomson, E., Kramer, I., Kneissel, M., Duda, G. N., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09653-9 · Cited by 43
Regulatory mechanisms of sclerostin expression during bone remodeling
Koide, M., & Kobayashi, Y. (2018) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-018-0971-7 · Cited by 50
Inducible expression of Wnt7b promotes bone formation in aged mice and enhances fracture healing
Song, D., He, G., Song, F., Wang, Z., Liu, X., Liao, L., Ni, J., Silva, M. J., & Long, F. (2020) · Bone Research · doi:10.1038/s41413-019-0081-8 · Cited by 49
Balemans, W., Foernzler, D., Parsons, C. A., Ebeling, M., Thompson, A., Reid, D. M., Lindpaintner, K., Ralston, S. H., & Hul, W. V. (2002) · Bone · doi:10.1016/s8756-3282(02)00844-x · Cited by 49
Weivoda, M. M., & Oursler, M. J. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0188-1 · Cited by 49
Fei, Y., & Hurley, M. M. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24075 · Cited by 70
van Bezooijen, R. L., DeRuiter, M. C., Vilain, N., Monteiro, R. M., Visser, A., van der Wee-Pals, L. J. A., van Munsteren, C. J., Hogendoorn, P. C. W., Aguet, M., Mummery, C. L., et al. (2006) · Developmental Dynamics · doi:10.1002/dvdy.21054 · Cited by 49
“Using reverse transcriptasepolymerase chain reaction (RT-PCR) analysis, however, SOST expression has been reported in human kidney and cartilage and at variable low levels in human aorta, bone marrow, heart, liver, lung, pancreas, placenta, and skin (Balemans et al., 2001; Brunkow et al., 2001).”
BackgroundMethodThe Role of Sclerostin in Bone and Ectopic Calcification
De Maré, A., D’Haese, P. C., & Verhulst, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093199 · Cited by 45
“In van Buchem disease patients, however, no disease-causing mutations were found within this gene [6,7].”
BackgroundSclerostin: From Molecule to Clinical Biomarker
Omran, A. S., Atanasova, D., Landgren, F., & Magnusson, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094751 · Cited by 55
“Two groups of researchers independently identified the SOST gene in 2001 [5,6].”
BackgroundSinha, P. S., Aarnisalo, P., Chubb, R., Poulton, I. J., Guo, J., Nachtrab, G. T., Kimura, T., Swami, S., Saeed, H., Chen, M., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.679753 · Cited by 46
“Canonical Wnt signaling plays a crucial role in regulating osteoblast differentiation and bone formation (14 –16), and patients lacking sclerostin have high bone mass (17, 18).”
BackgroundFrom disease to treatment: from rare skeletal disorders to treatments for osteoporosis
Appelman‐Dijkstra, N. M., & Papapoulos, S. E. (2016) · Endocrine · doi:10.1007/s12020-016-0888-7 · Cited by 52
“In 2001 two groups independently identified mutations in a new, rather small gene named SOST located on chromosome 17q12-21 that encodes for the protein sclerostin [58, 59].”
BackgroundPatsch, J., Kohler, T., Berzlanovich, A. M., Muschitz, C., Bieglmayr, C., Roschger, P., Resch, H., & Pietschmann, P. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.344 · Cited by 45
“Sclerostin, the SOST gene product, is a strong inhibitor of osteoblastogenesis and enhancer of osteoblast apoptosis.((55))”
BackgroundGregson, C. L., Bergen, D. J. M., Leo, P., Sessions, R. B., Wheeler, L., Hartley, A., Youlten, S., Croucher, P. I., McInerney-Leo, A. M., Fraser, W., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3875 · Cited by 44
“Sclerostin, a key inhibitor of bone formation, was discovered through study of two rare syndromes of extreme high bone mass (HBM) due to mutations in SOST.((5,6)) SOST encodes Sclerostin, which binds to low-density lipoprotein receptor-related proteins 5 and 6 (LRP5 and LRP6) to prevent activation of canonical WNT sig…”
BackgroundThe Biological Enhancement of Spinal Fusion for Spinal Degenerative Disease
Makino, T., Tsukazaki, H., Ukon, Y., Tateiwa, D., Yoshikawa, H., & Kaito, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082430 · Cited by 49
Heinke, J., Kerber, M., Rahner, S., Mnich, L., Laßmann, S., Helbing, T., Werner, M., Patterson, C., Bode, C., & Moser, M. (2011) · Oncogene · doi:10.1038/onc.2011.473 · Cited by 46
“, 2004), Sclerostin (Brunkow et al., 2001; Krause et al., 2010), twisted gastrulation (Tsg) (Oelgeschlager et al.”
BackgroundLRP5: From bedside to bench to bone
Williams, B. O. (2017) · Bone · doi:10.1016/j.bone.2017.03.044 · Cited by 46
Recent Advances in the Genetics of Fractures in Osteoporosis
Koromani, F., Trajanoska, K., Rivadeneira, F., & Oei, L. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00337 · Cited by 45
Sinha, P. S., Aarnisalo, P., Chubb, R., Ono, N., Fulzele, K. S., Selig, M. K., Saeed, H., Chen, M., Weinstein, L. S., Pajevic, P. D., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2270 · Cited by 47
“Ablation of Gsa in osteoprogenitors leads to increased levels of sclerostin, a potent inhibitor of canonical Wnt signaling and a promising target for osteoporosis therapy.((53,75,76)) Sclerostin is produced by osteocytes, cells derived from terminally differentiated osteoblasts and surrounded bymineralizedmatrix.”
BackgroundBalemans, W., & Hul, W. V. (2004) · PubMed · Cited by 43
Genetics of osteoporosis: searching for candidate genes for bone fragility
Rocha, M. G. M., & Ferraz‐de‐Souza, B. (2016) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000178 · Cited by 48
“In 2001, the breakthrough discovery of the involvement of the Wnt signalling pathway on the regulation of bone remodelling was made possible by the study of rare conditions such as osteoporosis-pseudoglioma syndrome (OPPG) due to LRP5 mutations (11) and sclerosteosis due to SOST defects (12,13).”
BackgroundGould, N. R., Williams, K. M., Joca, H. C., Torre, O. M., Lyons, J. S., Leser, J. M., Srikanth, M. P., Hughes, M., Khairallah, R. J., Feldman, R. A., et al. (2021) · eLife · doi:10.7554/elife.64393 · Cited by 43
Feng, J. B., Zhang, Q., Pu, F., Zhu, Z., Lu, K., Lu, W. W., Tong, L., Yu, H., & Chen, D. (2024) · Cell Proliferation · doi:10.1111/cpr.13600 · Cited by 43
Feng, G., Zhang, C., Yi-Min, C., & Li, X. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.11.010 · Cited by 41
The sclerostin-bone protein interactome
Ketha, H., Craig, T. A., Madden, B. J., Bergen, H. R., & Kumar, R. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.12.048 · Cited by 44
“the regulation of osteoblastic activity [1,2,3,4,5].”
BackgroundSclerostin-Neutralizing Antibody Enhances Bone Regeneration Around Oral Implants
Yu, S. H., Hao, J., Fretwurst, T., Liu, M., Kostenuik, P. J., Giannobile, W. V., & Jin, Q. (2018) · Tissue Engineering Part A · doi:10.1089/ten.tea.2018.0013 · Cited by 42
“9,10 11–13 Animal experiments on SOST -null mice have shown increased bone formation, bone mass, and bone strength, 14 while overexpression of the SOST gene in mice results in osteopenia.”
Sclerostin Directly Stimulates Osteocyte Synthesis of Fibroblast Growth Factor-23
Ito, N., Prideaux, M., Wijenayaka, A. R., Yang, D., Ormsby, R. T., Bonewald, L. F., & Atkins, G. J. (2021) · Calcified Tissue International · doi:10.1007/s00223-021-00823-6 · Cited by 45
Guañabens, N., Ruiz-Gaspà, S., Gifre, L., Miquel, R., Peris, P., Monegal, A., Dubrueil, M., Arias, A., & Parés, A. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2845 · Cited by 39
“highest levels of expression, but SOST low expression was also found in cartilage and adult liver.((24)) Interestingly, Cejka and colleagues found that sclerostin protein was detected in human renal tissue, using immunohistochemistry, predominantly in the proximal tubular cells,((28)) and others have found sclerostin…”
BackgroundEmerging Insights into the Endocrine Regulation of Bone Homeostasis by Gut Microbiome
Hansdah, K., & Lui, J. C. K. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae117 · Cited by 42
The Effect on Proliferation and Differentiation of Cementoblast by Using Sclerostin as Inhibitor
Bao, X., Liu, Y., Han, G., Zuo, Z., & Hu, M. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141021140 · Cited by 45
“As a member of the DAN (differential screening–selected gene aberrant in neuroblastoma) family of glycoproteins, sclerostin has a cysteine knot structure, which is believed to antagonize bone morphogenetic protein (BMP) activity [38,39].”
BackgroundBMP antagonists in tissue development and disease
Correns, A., Zimmermann, L. A., Baldock, C., & Sengle, G. (2021) · Matrix Biology Plus · doi:10.1016/j.mbplus.2021.100071 · Cited by 41
“Craniodiaphyseal dysplasia (CDD: OMIM#122860) [48], autosomal dominant sclerosteosis 1 (SOST1: OMIM#269500) [49], and Van Buchem disease (VBCH: OMIM#239100) [50] are caused by mutations in sclerostin (SOST).”
Background
Metadata
- Authors
- Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., Alisch, R. S., Gillett, L., Colbert, T., Tacconi, P., Galas, D., Hamersma, H., Beighton, P., & Mulligan, J. T.
- Affiliations
- University of Cape Town (ZA)
- University of Cagliari (IT)
- Corresponding author
- Brunkow, Mary E.
- ORCID
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2001-03
- Volume
- 68
- Issue
- 3
- Pages
- 577-589
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1274471
- OpenAlex
- W2037750372
- Cited by
- 1,011
- References
- 50
- Citations by year
- 2026: 24 · 2025: 21 · 2024: 32 · 2023: 27 · 2022: 36 · 2021: 53 · 2020: 52 · 2019: 46 · 2018: 50 · 2017: 56 · 2016: 65 · 2015: 61 · 2014: 58 · 2013: 60 · 2012: 56
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4523 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Dermatological and Skeletal Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Keywords
- sclerosteosis, SOST gene, skeletal dysplasia, cystine knot proteins, bone homeostasis, skeletal overgrowth, nonsense mutation, splicing mutation, founder effect, Afrikaner population, bone formation regulation
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Bone Diseases, Chromosome Mapping, Chromosomes, Human, Pair 17, Consanguinity, Cystine, Female, Genetic Markers, Homozygote, Humans, Male, Molecular Sequence Data, Netherlands, Pedigree, Proteins, Recombination, Genetic, Sclerosis, Senegal, South Africa, Conserved Sequence, Alternative Splicing, Bone Morphogenetic Proteins, Mutation, Missense, Black People, White People, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.